Compare American Financial Group Inc (AFG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Financial Group Inc vs BIO-TECHNE Corp — how do they compare? American Financial Group Inc trades at $141.32 (market cap $11.86B), while BIO-TECHNE Corp trades at $70.56 (market cap $11.00B). The key difference: American Financial Group Inc and BIO-TECHNE Corp are close in size by market cap, and American Financial Group Inc pays the higher dividend (2.46%). Which is the better fit depends on your goals.
| AFG | TECH | |
|---|---|---|
Market Cap | $11.86B | $11.00B |
Sector | Financials | Health |
52-Week High | $148.71 | $71.38 |
52-Week Low | $122.42 | $43.31 |
Enterprise Value | $12.33B | $11.08B |
Dividend Yield | 2.46% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFG trades at $142.80, up 0.04% with a bullish technical outlook. The stock shows strong profitability with 10.84% net margin and 19.38% ROE, though Q1 2026 earnings missed estimates. Recent dividend declarations of $0.88 per share highlight shareholder returns. Analyst consensus is mixed with 41% buy ratings and a $149 price target, representing 4.3% upside from current levels.
AFG offers moderate upside potential with solid fundamentals and consistent dividends, but faces execution risks after recent earnings miss. The insurance sector exposure provides stability, though competitive pressures and regulatory changes remain key watchpoints for investors seeking steady returns with income generation.
Bio-Techne (TECH) trades at $70.61, down 0.3% on the day, near its $73.00 takeover offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with strong moving averages, though RSI levels indicate overbought conditions. Fundamentals reveal a high P/E of 101.29 and declining net margins, but revenue remains stable near $1.22 billion. Cash flow improved in 2025 with $10.40M net inflow, and the balance sheet holds $152.86M cash against $319M long-term debt.
Outlook is dominated by the pending acquisition, offering a clear exit at $73.00, a 3.4% premium to current price. Risks include shareholder litigation questioning deal fairness and margin pressures. Analysts are unanimously positive with no sell ratings, seeing limited downside given the buyout bid. The stock presents a low-risk opportunity if the deal closes, but investors face uncertainty from legal challenges and earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
